US5219740A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Retroviral gene transfer into diploid fibroblasts for gene therapy
Assignee: Fred Hutchinson Cancer Center
•
Filing: 1987-02-13
•
Granted: 1993-06-15
•
Expires: 2007-02-13
Abstract
Abstract A process of mammalian gene therapy. Explanted fibroblasts are genetically modified by introducing a retroviral construct containing a nucleotide sequence encoding for a therapeutic substance. The genetically modified fibroblasts are implanted into a mammalian subject.
Inventors
- 👤 A. Dusty Miller
- 👤 Theo D. Palmer
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 11:28
CPC Classifications
C; C12; C12N; C12N15/00; C12N15/09; C12N15/63; C12N15/79; C12N15/85; C12N15/86; A; A61; A61K; A61K48/00; A61K49/00; C12N2740/00; C12N2740/00011; C12N2740/10011; C12N2740/13011; C12N2740/13041; C12N2740/13043
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
139 words
A process of gene transfer into diploid fibroblasts in vitro, comprising the step of: genetically modifying diploid fibroblasts explanted from a mammalian subject by a process consisting essentially of introducing into said fibroblasts a retroviral construct comprising a first nucleotide sequence encoding a first expression product, a viral long terminal repeat and a promoter sequence upstream of said first nucleotide sequence, and a viral long terminal repeat and a polyadenylation sequence downstream of said first nucleotide sequence, wherein said retroviral construct lacks one or more of the gag, pol, and env sequences required for retroviral replication, by contacting said fibroblasts with said retroviral construct in a virus-containing medium having a viral titer of at least about 10 5 cfu/ml on NIH 3T3 fibroblasts to produce a population of fibroblasts at least 1% of which express said first expression product.
Claim 2
Dependent Claim
139 words
A process of gene transfer into diploid fibroblasts in vitro, comprising the step of: genetically modifying diploid fibroblasts explanted from a mammalian subject by a process consisting essentially of introducing into said fibroblasts a retroviral construct comprising a first nucleotide sequence encoding a first expression product, a viral long terminal repeat and a promoter sequence upstream of said first nucleotide sequence, and a viral long terminal repeat and a polyadenylation sequence downstream of said first nucleotide sequence, wherein said retroviral construct lacks one or more of the gag, pol, and env sequences required for retroviral replication, by contacting said fibroblasts with said retroviral construct in a virus-containing medium having a viral titer of at least about 10 5 cfu/ml on NIH 3T3 fibroblasts to produce a population of fibroblasts at least 1% of which express said first expression product.
Claim 3
Dependent Claim
38 words
The process of claim 1, wherein said retroviral construct further comprises a second nucleotide sequence encoding a second expression product, and wherein one of the first and the second expression products confers resistance to a selectable marker substance.
Claim 4
Dependent Claim
20 words
The process of claim 2, wherein said selectable marker substance is selected from the group consisting of G418 and Hygromycin-B.
Claim 5
Dependent Claim
18 words
The process of claim 1, wherein said diploid fibroblasts are explanted from the tissue of a mammalian subject.
Claim 6
Dependent Claim
12 words
The process of claim 1, wherein said mammalian subject is a human.
Claim 7
Dependent Claim
28 words
The process of claim 2, wherein the other of the first and the second expression products is selected from the group consisting of enzymes, hormones, and precursors thereof.
Claim 8
Dependent Claim
32 words
The process of claim 6, wherein the other of the first and the second expression products is selected from the group consisting of adenosine deaminase, purine nucleoside phosphorylase, and blood clotting factors.
References Cited (Backward Citations)
US4396601A
Cited
US4497796A
Cited
US4485096A
Cited
US4686098A
Cited
WO1987000201A1
Cited
US4868116A
Cited
US4861719A
Cited
WO1989002468A1
Cited
WO1989007136A2
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1996-06-14 | 1996-12-14 | 1997-06-15 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2000-06-14 | 2000-12-14 | 2001-06-15 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2004-06-14 | 2004-12-14 | 2005-06-15 | $7700.00 | Window Closed / Lapsed |